1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Indian Immunologicals Limited - Product Pipeline Review - 2016

Indian Immunologicals Limited - Product Pipeline Review - 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 29 pages

Indian Immunologicals Limited - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Indian Immunologicals Limited - Product Pipeline Review - 2016’, provides an overview of the Indian Immunologicals Limited’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Indian Immunologicals Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Indian Immunologicals Limited
- The report provides overview of Indian Immunologicals Limited including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Indian Immunologicals Limited’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Indian Immunologicals Limited’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Indian Immunologicals Limited’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Indian Immunologicals Limited
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Indian Immunologicals Limited’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table Of Contents

Indian Immunologicals Limited - Product Pipeline Review - 2016
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Indian Immunologicals Limited Snapshot 5
Indian Immunologicals Limited Overview 5
Key Information 5
Key Facts 5
Indian Immunologicals Limited - Research and Development Overview 6
Key Therapeutic Areas 6
Indian Immunologicals Limited - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Combination Treatment Modalities 10
Indian Immunologicals Limited - Pipeline Products Glance 11
Indian Immunologicals Limited - Clinical Stage Pipeline Products 11
Phase I Products/Combination Treatment Modalities 11
Indian Immunologicals Limited - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Indian Immunologicals Limited - Unknown Stage Pipeline Products 13
Unknown Products/Combination Treatment Modalities 13
Indian Immunologicals Limited - Drug Profiles 14
(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
chikungunya vaccine 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
human papillomavirus [serotypes 16, 18] vaccine 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
Japanese encephalitis vaccine 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
Alphavirus vaccine 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
flavivirus vaccine 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
picornavirus vaccine 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
Vaccine for Undisclosed Indication 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Indian Immunologicals Limited - Pipeline Analysis 22
Indian Immunologicals Limited - Pipeline Products by Target 22
Indian Immunologicals Limited - Pipeline Products by Route of Administration 23
Indian Immunologicals Limited - Pipeline Products by Molecule Type 24
Indian Immunologicals Limited - Recent Pipeline Updates 25
Indian Immunologicals Limited - Dormant Projects 26
Indian Immunologicals Limited - Locations And Subsidiaries 27
Head Office 27
Other Locations and Subsidiaries 27
Appendix 28
Methodology 28
Coverage 28
Secondary Research 28
Primary Research 28
Expert Panel Validation 28
Contact Us 28
Disclaimer 29

List of Tables
Indian Immunologicals Limited, Key Information 5
Indian Immunologicals Limited, Key Facts 5
Indian Immunologicals Limited - Pipeline by Indication, 2016 7
Indian Immunologicals Limited - Pipeline by Stage of Development, 2016 8
Indian Immunologicals Limited - Monotherapy Products in Pipeline, 2016 9
Indian Immunologicals Limited - Combination Treatment Modalities in Pipeline, 2016 10
Indian Immunologicals Limited - Phase I, 2016 11
Indian Immunologicals Limited - Preclinical, 2016 12
Indian Immunologicals Limited - Unknown, 2016 13
Indian Immunologicals Limited - Pipeline by Target, 2016 22
Indian Immunologicals Limited - Pipeline by Route of Administration, 2016 23
Indian Immunologicals Limited - Pipeline by Molecule Type, 2016 24
Indian Immunologicals Limited - Recent Pipeline Updates, 2016 25
Indian Immunologicals Limited - Dormant Developmental Projects,2016 26
Indian Immunologicals Limited, Other Locations 27

List of Figures
Indian Immunologicals Limited - Pipeline by Top 10 Indication, 2016 7
Indian Immunologicals Limited - Pipeline by Stage of Development, 2016 8
Indian Immunologicals Limited - Monotherapy Products in Pipeline, 2016 9
Indian Immunologicals Limited - Pipeline by Route of Administration, 2016 23
Indian Immunologicals Limited - Pipeline by Molecule Type, 2016 24

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H2 2016

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H2 2016’, provides ...

Mycobacterium tuberculosis Protein Ag85A - Pipeline Review, H2 2016

Mycobacterium tuberculosis Protein Ag85A - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Mycobacterium tuberculosis Protein Ag85A - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Mycobacterium tuberculosis Protein Ag85A - Pipeline Review, H2 2016’, provides in depth analysis ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.